How to Increase Prescription Share of Voice with AI
Share of voice and share of prescriptions are two different things, and conflating them is the most common error in this subject. Share of voice is your share of the total promotional and scientific communication a doctor receives. Share of prescriptions is your share of what they actually write. The framework linking them — excess share of voice, where SOV minus share of market predicts share growth — is the best available model and its evidence base is weaker than most guidance implies: no public coefficients, largely secondary citation, and explicitly necessary but not sufficient. What that means practically is that buying more voice is the expensive lever and making voice more relevant is the effective one — which is exactly where AI contributes.
Share of voice and share of prescriptions are not the same thing
Worth separating carefully, because the article's title contains the confusion and so does most of the category's vocabulary.
| Metric | What it measures | How it is captured | What it is for |
|---|---|---|---|
| Share of voice (SOV) | Your share of the total promotional and scientific communication reaching a doctor, across every channel and competitor | Historically promotional spend or call volume. Properly, share of attention received | A leading indicator. Tells you whether you are present in the conversation |
| Share of mind | Your share of what the doctor recalls and associates with the clinical problem | Survey, recall testing, unaided mention | The bridge between voice and behaviour, and the least measured of the three |
| Share of prescriptions (Rx share) | Your share of scripts actually written in the category | Prescription panel data where it exists; sales proxies where it does not | A lagging outcome. Tells you what happened |
| Excess share of voice (ESOV) | SOV minus share of market — whether you are speaking above or below your weight | Both of the above, in the same category definition | The planning metric. Directional guidance on whether investment supports growth |
The distinction is not academic. A brand manager told that share of voice drives prescriptions will buy more voice — more calls, more media, more frequency. A brand manager who understands that voice is one necessary input among several will ask a different and better question: is our voice being heard, and is it saying something that changes a prescribing decision?
Share of mind is the neglected middle term. It is the only one of the three that tests whether the voice landed, and almost nobody in Indian pharma measures it — which means most SOV programmes have no way of knowing whether increased spend produced increased presence in the doctor's head or simply increased noise.
The ESOV principle, and what the evidence actually supports
This is the framework everything in the category rests on, so it is worth reporting accurately rather than enthusiastically.
Direct answer ESOV = SOV − SOM. Brands whose share of communication exceeds their share of market tend to grow share over time; brands investing materially below their share of market risk decline. The framework is credible, widely used, and derived from industry effectiveness research associated with practitioners including Les Binet and Peter Field, building on earlier panel-data work by John Philip Jones. It is also necessary but not sufficient — the framework's own literature states plainly that quality, availability and pricing still determine the outcome, and that media alone will not sustain share gains in categories dominated by price and promotion. |
Five conditions the consulting version tends to omit
| Condition | What it means | Why it matters in pharma specifically |
|---|---|---|
| No public coefficients | The framework's own guidance advises estimating share movement per ESOV point from your own historicals and to set ranges rather than absolutes. Effect sizes from the original panel work are not publicly disclosed | Any vendor quoting a precise conversion rate is inventing one. Treat specific ratios as unsupported |
| Category variation | Not all categories respond uniformly | Pharma is a high-consideration, evidence-led, professionally-mediated purchase. It should not be assumed to behave like packaged goods |
| Niche B2B effects are slower | Effects materialise more slowly at buying-centre level in narrow professional markets | A prescribing universe of a few thousand specialists is the definition of niche B2B. Expect longer lags and smaller signals |
| Creative quality is a multiplier | Excess voice works considerably better when carrying strong creative and considerably worse otherwise | The single most important condition for this article. In pharma, relevance and clinical credibility are the analogue of creative quality |
| Selection in the evidence base | Calculations exclude brands that grew with little advertising support, and the model needs econometric validation because SOV is rarely the only explanatory variable | Argues for measuring your own effect rather than importing a general one — which is what the measurement guide sets out |
The conclusion a brand manager should draw ESOV is worth using as a planning check — if your share of voice sits materially below your share of market, that is a defensible reason to argue for investment, and it is the strongest such argument available. It is not worth using as a forecast. Nobody can tell you how many share points a given increase in voice will buy, the framework's own literature declines to, and the conditions under which it works least well — niche professional audiences, evidence-led decisions, weak differentiation between messages — describe pharma unusually accurately. Use it to justify not being outshouted. Do not use it to promise a number. |
How to measure share of voice among doctors
The measurement question comes before the tactics question, because a programme that cannot measure SOV is optimising a number it has assumed.
The historical measure was promotional spend or call volume — your calls as a share of all calls the doctor received. That was a reasonable proxy when the rep visit was effectively the only channel. It is now a proxy for a shrinking share of the communication a doctor actually receives, and it systematically overstates the voice of companies with large field forces and understates everyone else.
| Measure | What it captures | Strength | Blind spot |
|---|---|---|---|
| Call share | Your calls as a share of all detailing that doctor receives | Easy, and the only measure most Indian brands have | Requires competitor call data, which comes from rep reporting and is systematically unreliable. Ignores every other channel |
| Promotional spend share | Your category spend against total estimated category spend | Aligns with the ESOV framework as classically defined | Measures money, not attention. A large budget spent badly registers as high voice |
| Digital presence share | Your share of digital touchpoints reaching the target universe | First-party and objective on your side | Competitor digital activity is hard to observe. Partial picture |
| Scientific share of voice | Your share of publications, congress presence, guideline mentions and KOL activity in the therapy area | Highly measurable from public sources, and often the more meaningful voice in specialty categories | Slow-moving. Reflects investment made years earlier |
| Social and community listening | Your share of what is being said about the category in physician communities and public channels | Captures voice you did not pay for, including negative | Coverage of closed professional channels is limited |
| Share of attention | Estimated share of the doctor's finite engagement capacity that you occupy | The measure that actually matters — combines reach, engagement depth and recall | Hardest to construct. Requires first-party engagement data and preferably recall testing |
The practical recommendation is to build a composite rather than pick one. Scientific share of voice plus digital presence share plus call share, weighted for your category, gives a far more honest picture than spend alone — and the first of those three is measurable from public sources without any competitor cooperation, which makes it the best available objective anchor.
The deeper point is that voice has moved from something you buy to something you earn and something you occupy. A measurement built on spend cannot see that shift, which is why brands that feel they are outspending competitors and losing ground often are — they are buying voice and losing attention.
A share-of-voice scorecard you can actually build
The composite is only useful if someone can compute it on a Monday morning from data the company already holds. This is the version that survives contact with a real brand team.
| Component | Weight (specialty) | Weight (mass-market) | Source | Refresh |
|---|---|---|---|---|
| Scientific share of voice | 40% | 20% | Publication databases, congress programmes, guideline documents, society listings — all public | Quarterly |
| Digital presence share | 30% | 30% | First-party engagement volume against an estimated category denominator | Monthly |
| Call share | 30% | 50% | Own field reporting plus competitor call estimates from structured rep observation | Monthly |
Two weighting sets, because the honest answer depends on the category. In specialty, scientific voice is the dominant channel and the field force is a delivery mechanism for it. In mass-market primary care the call remains the dominant channel and the weighting inverts. Pick the set that matches your category, write down why, and do not change it mid-year — a composite whose weights move is a number that can be made to say anything.
The denominator is the hard part, and you must write down how you estimated it Every share measure needs a category total, and no Indian brand has an observed one. You are estimating the denominator, and the estimate is where the argument will happen in the review meeting. The defensible approach is to state the basis in one line next to the number — for example, category call volume estimated from published field-force sizes and an assumed calls-per-day figure, or category digital volume estimated from competitor campaign observation. A number with a stated basis can be challenged and improved. A number without one gets discarded the first time someone senior disagrees with it. Scientific share of voice is the exception, and that is precisely why it anchors the composite: the denominator is countable from public sources. |
A worked ESOV calculation, end to end
Everything above is abstract until someone computes it. What follows is a full worked calculation for an illustrative brand — a mid-market cardiology product in a defined therapy segment, competing against six named companies. The figures are constructed to demonstrate the method, not reported from a client engagement. Substitute your own and the arithmetic is identical.
Step 1 — fix the category and the universe
| Decision | This example | Why it matters |
|---|---|---|
| Therapy segment | One antiplatelet segment, not the whole cardiology portfolio | A wider category definition mechanically lowers your share of voice and makes every subsequent number look worse than it is |
| Competitor set | Six companies holding a combined 71% of segment value | Excluding small competitors is defensible; excluding a large one to flatter the number is not |
| Doctor universe | 2,140 cardiologists and consulting physicians in the covered geographies | The denominator for every voice measure. Define it once and reuse it everywhere |
| Period | Two full quarters | Shorter periods read seasonal promotion cycles as share movement |
Step 2 — compute each voice component
| Component | Your volume | Estimated category volume | Your share | Basis of the denominator |
|---|---|---|---|---|
| Scientific SOV | 14 attributable publications, congress slots and guideline citations | 190 in the segment over the period | 7.4% | Counted from public sources. Observed, not estimated |
| Digital presence | 3,200 delivered digital touchpoints to the defined universe | 26,000 estimated | 12.3% | Estimated from competitor campaign observation and channel benchmarks |
| Call share | 4,800 calls per month into the universe | 41,000 estimated | 11.7% | Estimated from published field-force sizes and an assumed calls-per-day figure |
Step 3 — weight, and subtract
| Line | Working | Result |
|---|---|---|
| Weighted composite SOV (specialty weights) | (0.40 × 7.4) + (0.30 × 12.3) + (0.30 × 11.7) = 2.96 + 3.69 + 3.51 | 10.2% |
| Share of market (segment value) | Reported secondary sales share | 13.5% |
| Excess share of voice | 10.2 − 13.5 | −3.3 points |
| Sensitivity check at mass-market weights | (0.20 × 7.4) + (0.30 × 12.3) + (0.50 × 11.7) = 11.0%, less 13.5% | −2.5 points |
The direction is robust and the magnitude is not. Under either weighting the brand is communicating below its weight, which is the finding that matters. The gap is 3.3 points or 2.5 points depending on assumptions you chose, which is exactly why the framework's own guidance advises presenting ranges rather than absolutes. Report it as “between two and three and a half points below weight” and the number survives scrutiny.
Step 4 — read the components, not just the total
This is the step most teams skip, and it carries most of the value. The composite says the brand is under-communicating by roughly three points. The components say something far more actionable.
| Component | Share | Against SOM of 13.5% | What it implies |
|---|---|---|---|
| Scientific SOV | 7.4% | 6.1 points below weight | The deficit is concentrated here. In a specialty segment this is the component that most shapes prescriber belief — and the slowest to correct, because publications and congress presence reflect investment made one to three years earlier |
| Digital presence | 12.3% | 1.2 points below | Roughly at weight. Not the problem, and increasing it will not close the gap |
| Call share | 11.7% | 1.8 points below | Close to weight against a much larger competitor field force — this is already an efficient position and hard to improve further |
The decision this calculation actually produces A brand manager reading only the headline −3.3 would ask for more budget, and would most likely spend it on calls or digital, because those are the levers a quarterly plan can move. The component read says the money would go to the two components already close to weight, and would leave the six-point deficit untouched. The correct response is two-track: a medical and publications plan that will take eighteen months to register, and message-relevance work on the existing spend that can register this quarter. That second track is where AI contributes, and the reason is in the framework itself — message quality multiplies the effect of the voice you already have. A brand that cannot close a scientific voice gap for two years can still raise its effective share of voice immediately. |
How can AI increase prescription share?
Not by producing more communication. AI raises the efficiency with which voice converts to attention, which is the mechanism the ESOV framework identifies as the multiplier and which most implementations ignore. Concretely, AI helps in four places: selecting who to reach so that voice lands on doctors whose patients fit the brand; selecting what to say so the message matches the doctor's clinical situation and adoption stage; selecting when and where so the message arrives through a channel that doctor actually uses; and detecting share movement early so the response happens in weeks rather than after a quarterly review. The lever is relevance, not volume.
The reasoning follows directly from the evidence. If excess share of voice works substantially better when it carries a strong message, then the return on improving message-to-doctor fit is a multiplier on all existing spend rather than an addition to it. For a brand that cannot outspend its competitors — which is most brands — that is the only available route to effective share of voice growth.
The reframe worth taking to a budget conversation
A doctor has a fixed amount of professional attention and an effectively unlimited supply of people wanting it. Share of voice is therefore a competition for a scarce resource, and you can compete on volume or on relevance.
Competing on volume means outspending companies that may have ten times your field force. Competing on relevance means each interaction consumes more of that finite attention because it is worth the doctor's time.
A brand with a third of a competitor's spend and twice its message relevance can hold comparable share of attention. That proposition is testable, it is consistent with what the ESOV literature says about creative quality, and it is the only version of this strategy available to a challenger brand.
GET ACTIONABLE AI AND HEALTHCARE INSIGHTS THAT HELP YOU STAY AHEAD IN A FAST-CHANGING PHARMA WORLD
AI tactics to grow brand share among prescribers
Eight tactics, ordered by how quickly they produce a measurable effect. Each states what it needs, because several require data an Indian brand may not hold.
| # | Tactic | What it does | Needs | Time to effect |
|---|---|---|---|---|
| 1 | Message-to-doctor matching | Selects which approved message a given doctor sees, based on specialty, patient mix and expressed clinical interest | Approved modular content plus a doctor 360 | Fast — weeks. Highest return for lowest prerequisite |
| 2 | Channel fit modelling | Routes each doctor through the channel they demonstrably respond to rather than the channel you prefer | Two quarters of first-party engagement history | Fast. Frequently reorders the target list more than any other change |
| 3 | Engagement decay alerts | Flags doctors whose engagement is falling against their own baseline, before the outcome moves | Consistent engagement time series | Fast, and the strongest early-warning signal available without Rx data |
| 4 | Scientific SOV monitoring | Tracks your share of publications, congress presence and guideline mentions against competitors | Public source monitoring | Medium. Reflects investment made years earlier, so it guides medium-term strategy |
| 5 | Competitive message detection | Identifies when a competitor changes its claim or launches a campaign, from public and field signals | Social listening plus structured rep intelligence | Medium |
| 6 | Look-alike expansion | Finds untouched doctors resembling your best adopters — voice directed at people likely to respond | A defined seed set and a doctor 360 | Medium. Addresses the cold-start problem that rep-rated targeting cannot |
| 7 | Sequence optimisation | Learns which order of messages moves doctors along the adoption ladder fastest | Closed-loop capture with outcomes | Slow. Requires the loop to be closed first |
| 8 | Share-shift attribution | Estimates which competitor is gaining at your expense and where | Territory-level outcome data at minimum | Slow, and the most valuable. See the next section |
Tactics one to three are available to almost any brand with a clean doctor database and first-party engagement data, and they are where a programme should start. Tactic three deserves particular attention in markets without prescription data, because engagement decay against a doctor's own baseline is the earliest observable signal that something has changed in that relationship — and it appears well before any sales number moves.
How do I know which competitor is taking my share?
The most commercially urgent question in this article, and the one where the answer differs most sharply depending on what data you have.
Where prescriber-level prescription data exists
The classical method is source of business analysis — decomposing your share change into its components rather than reading the net number.
| Component | The question | What it tells you |
|---|---|---|
| New to category | Patients newly starting therapy who chose you | Whether you win at the moment of first decision. A weakness here is a message problem |
| Switch in | Patients moving to you from a named competitor | Who you are beating, and on what. Segment by source brand |
| Switch out | Patients moving from you to a named competitor | The number that answers the question. Who is taking your share, specifically |
| Retention | Patients staying on your therapy | Whether the problem is acquisition or leakage. These require completely different responses |
The diagnostic value is in the decomposition. A brand losing share through switch-out to one competitor has a competitive-response problem. A brand losing share because new-to-category patients are choosing elsewhere has a positioning problem. The net share number looks identical in both cases and the correct action is completely different.
Where it does not — the Indian version
Without prescriber-level prescription data you cannot decompose source of business per doctor, and there is no technique that recovers it. What you can do is triangulate from four weaker signals that are individually unreliable and jointly informative: territory-level share movement correlated with competitor field activity, structured competitive intelligence from reps, engagement decay patterns at doctor level, and chemist-proximity sales shifts around specific clinics. No single one is evidence. A consistent pattern across three of the four is.
| Signal | How to capture it | What it can and cannot tell you |
|---|---|---|
| Territory share movement | Secondary sales by territory against category, compared with competitor field-force changes and campaign timing | Can identify where share is moving and roughly when. Cannot identify which doctors |
| Structured competitive intelligence | Reps record competitor activity against a fixed schema — which competitor, which message, which doctor, what changed — rather than free text | The most under-used asset in Indian pharma. Reps see competitor activity daily and it is almost never captured in analysable form |
| Engagement decay at doctor level | Response rate against that doctor's own baseline across channels, tracked continuously | The earliest signal available. A doctor disengaging is often a doctor being engaged elsewhere |
| Chemist-proximity sales shift | Sales movement at the outlets nearest a specific clinic, against the territory trend | Noisy and genuinely informative when a clinic's surrounding outlets move against the local trend |
Fix the competitive intelligence capture first
Of the four signals, structured competitive intelligence is the one most brands could improve this quarter at no cost. Reps already observe which competitor was in the clinic, which message they led with, and which doctors have changed their questions. It is captured as free text in call notes, if at all, and is therefore unanalysable.
Replacing that with four structured fields — competitor, message theme, doctor, observed change — turns thousands of daily observations into a dataset that can be aggregated by territory and therapy area.
No AI is required to start. The AI value comes later, in detecting patterns across the aggregate — and it cannot be applied to a field of free text nobody has ever read.
A worked switch diagnosis
The triangulation method is only convincing when someone has seen it run. The following is an illustrative walkthrough of a brand losing 1.1 share points across two quarters in a market with no prescriber-level prescription data — the situation most Indian brand teams are actually in. The figures demonstrate the method rather than report a client engagement.
| Signal | What the data showed | Reading |
|---|---|---|
| 1. Territory share movement | Three of fourteen territories accounted for roughly 80% of the decline. All three sit in one metro cluster. A competitor added four representatives to that cluster at the start of the period | The loss is local, not national. Timing coincides with a specific competitor's field expansion |
| 2. Structured competitive intelligence | In those three territories, 61 rep observations named one competitor, and 44 of them cited the same message theme — a new head-to-head safety claim. In the other eleven territories that competitor appeared in 9% of observations | Names the competitor and, more usefully, names the claim. The concentration difference is the finding |
| 3. Engagement decay | 38 of 210 target doctors in the cluster showed response rates more than 40% below their own twelve-month baseline. 29 of the 38 were high-value prescribers | Narrows a territory-level problem to twenty-nine named doctors. No other signal can do this |
| 4. Chemist-proximity shift | Outlets within one kilometre of twelve of those twenty-nine clinics showed category-adjusted sales for the brand down 9%, against a territory trend of −2% | Consistent with the other three. Noisy on its own and corroborating in combination |
Four signals agree on the same story: one competitor, one metro cluster, one clinical claim, concentrated in twenty-nine identifiable doctors. None of the four would be sufficient alone. Signal one cannot name doctors, signal two is observational and subject to rep bias, signal three shows disengagement without saying where the attention went, and signal four is noisy at the outlet level. Their agreement is the evidence
What this still cannot tell you, and should not be presented as telling you
- Whether the loss is switch-out or new-patient share. Without prescriber-level data the decomposition remains unavailable, and the two require different responses. The triangulation localises the problem; it does not decompose it.
- Whether those twenty-nine doctors switched or simply reduced overall prescribing. A doctor writing less of everything looks identical in this method to a doctor writing more of a competitor.
- Whether the safety claim caused the movement or merely accompanied it. Field expansion and a new claim arrived together, and this method cannot separate them. The response should address both.
The commercial value is in what it stops you doing Read as a national number, a 1.1-point share decline argues for a national campaign, a national message refresh, and a budget conversation covering the whole field force. The diagnosis localises the same decline to one metro cluster, one competitor, one clinical claim and twenty-nine named doctors. The response is a medical-affairs answer to a specific claim, delivered to a specific list, measured against the eleven territories that did not move. That is a fraction of the cost, it is measurable because the unaffected territories form a natural control group, and it is available to any brand willing to structure its competitive intelligence capture. The saving is not in what the analysis finds — it is in the national spend it prevents. |
Where share-of-voice strategy fails
- Treating SOV as a target rather than a diagnostic. A brand that sets share of voice as its objective will buy voice, and buying voice is the expensive lever with the weakest evidential support. SOV is a check on whether investment is adequate, not a goal in itself.
- Measuring voice by spend. Money spent is not attention received, and a measurement built on spend cannot see the difference. Brands that feel they are outspending and losing ground are usually right about both.
- Ignoring share of mind entirely. The middle term is the only one that tests whether the voice landed. Skipping it means a programme can double its spend, double its measured SOV and change nothing in the doctor's head, with no mechanism to detect that.
- Assuming the ESOV relationship is stronger than the evidence supports. No public coefficients, secondary citation, necessary-but-not-sufficient, and slower effects in niche professional markets. Promising share points per point of voice is a promise nobody can keep.
- Competing on volume against a larger field force. A structurally losing strategy for a challenger brand, and the one most brand plans default to because it is the easiest to write.
- Reading net share movement without decomposition. Losing share to switch-out and losing share on new-to-category patients look identical in the net number and require opposite responses.
- Free-text competitive intelligence. Thousands of daily observations from the field, recorded in a format nobody can aggregate. The most valuable dataset in the company, discarded on capture.
A 90-day plan
Ordered so that the measurement exists before the tactics that depend on it.
- Days 1–15: define the category and compute your baseline honestly. Which competitors, which therapy area, which doctor universe. Category definition determines every number that follows and is usually decided casually. Compute current share of voice on the best measure available, and state its limitations in writing.
- Days 16–30: build a composite SOV measure. Scientific share of voice from public sources, digital presence share from first-party data, call share from field reporting. Scientific SOV is the best objective anchor because it needs no competitor cooperation.
- Days 31–45: restructure competitive intelligence capture. Four structured fields replacing free text. Brief the field on why. This is the highest-value fortnight in the plan and it costs nothing.
- Days 46–60: deploy the three fast tactics. Message-to-doctor matching, channel fit modelling, engagement decay alerts. All three run on data you already hold if the doctor database is clean.
- Days 61–75: run the switch diagnosis. Triangulate the four signals across your largest three territories. Look for pattern agreement, not for a single conclusive number — you will not find one.
- Days 76–90: set up the measurement that will judge this. A matched-territory comparison, because share movement without a control group is market movement wearing your logo. Agree the read-out date with finance before you start.
One expectation to set at the outset. Share movement is slow, and slower in niche professional markets. A 90-day plan builds the instrumentation and deploys the fast tactics; it does not deliver a share result. Teams that promise a share number in a quarter will be reporting noise, and the framework's own literature would predict exactly that.
Frequently Asked Questions For Increase Prescription Share of Voice with AI
GET ACTIONABLE AI AND HEALTHCARE INSIGHTS THAT HELP YOU STAY AHEAD IN A FAST-CHANGING PHARMA WORLD
Let's Discuss Your Requirements
